SeaStar Medical Holding Corporation, known on the Nasdaq as ICU, has announced significant changes to its Board of Directors. On June 5, 2024, John Neuman was appointed as a Class I director following the resignation of Andres Lobo. Neuman, a former Vice President of Global Financial Accounting at Dow Chemical Company, brings extensive experience in financial accounting and reporting. Additionally, two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected during the Company's 2024 Annual Meeting of Stockholders on June 4. The appointments come as former directors Bruce Rodgers and Richard Russell did not seek reelection, and Lobo retired from Dow Chemical, leading to his departure from the board. The new directors are expected to contribute their leadership and industry experience...Show More

SeaStar Medical Holding Corporation, known on the Nasdaq as ICU, has announced significant changes to its Board of Directors. On June 5, 2024, John Neuman was appointed as a Class I director following the resignation of Andres Lobo. Neuman, a former Vice President of Global Financial Accounting at Dow Chemical Company, brings extensive experience in financial accounting and reporting. Additionally, two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected during the Company's 2024 Annual Meeting of Stockholders on June 4. The appointments come as former directors Bruce Rodgers and Richard Russell did not seek reelection, and Lobo retired from Dow Chemical, leading to his departure from the board. The new directors are expected to contribute their leadership and industry experience as SeaStar Medical transitions to a commercial-stage company. The company issued a press release on June 10, 2024, detailing these board changes and highlighting the professional backgrounds of the new members. SeaStar Medical is a commercial-stage medical technology company focused on developing extracorporeal therapies to mitigate the effects of excessive inflammation on vital organs.